Lantern Pharma Posts New Data and Development Focus for LP-100 with PARP Inhibitors

Areteia Therapeutics Starts Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma

New Study Finds That Masimo PVi Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery

Diamyd Medical adds Karin Rosen to Board of Directors as adjunct member

AstraZeneca reports trial results showing Imfinzi improves lung cancer survival

Boehringer Ingelheim and Eli Lilly announce FDA acceptance of Jardiance supplemental New Drug Application

AuraVax Therapeutics names new chief executive officer

Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial

Viz.ai to Expedite Patient Enrollment in NIH-Funded PE-TRACT Clinical Trial

MacKinnon Named CEO at Saranas

Maze Therapeutics Touts Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Roche announces receipt of FDA approval for label expansion of VENTANA PD-L1 (SP263) Assay

US FDA approves Roche's label expansion for VENTANA PD-L1 (SP263) Assay for identification of NSCLC patients eligible for treatment with Libtayo

US Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Biodesix to Participate at Cowen's 43rd Annual Healthcare Conference